Cannabis Stock News Bite - Tilray Brands, Inc. (Nasdaq: TLRY) (TSX: TLRY) Gains in Morning Trading

Cannabis Stock News Bite - Tilray Brands, Inc. (Nasdaq: TLRY) (TSX: TLRY) Gains in Morning Trading: Cannabis Stock News Bite - Tilray Brands, Inc. (Nasdaq: TLRY) (TSX: TLRY) Gains in Morning Trading

Cannabis Stock News Bite - Investors High on Cannabis Stock Gains - Canopy Growth Corporation (TSX: WEED) (Nasdaq: CGC) up over 20%

Cannabis Stock News Bite - Investors High on Cannabis Stock Gains - Canopy Growth Corporation (TSX: WEED) (Nasdaq: CGC) up over 20%: Cannabis Stock News Bite - Investors High on Cannabis Stock Gains - Canopy Growth Corporation (TSX: WEED) (Nasdaq: CGC) up over 20%

Cannabis Stock News Bite - Curaleaf Holdings (TSX: CURA) Gives Struggling Cannabis Stocks a Win on News

Cannabis Stock News Bite - Curaleaf Holdings (TSX: CURA) Gives Struggling Cannabis Stocks a Win on News: Cannabis Stock News Bite - Curaleaf Holdings (TSX: CURA) Gives Struggling Cannabis Stocks a Win on News

Cannabis Stock News Bite - Incannex (NASDAQ: IXHL) Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorde

Cannabis Stock News Bite - Incannex (NASDAQ: IXHL) Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorde: Cannabis Stock News Bite - Incannex (NASDAQ: IXHL) Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder

Revolution Cannabis Workers Ratify Contract With Teamsters Local 777

Revolution Cannabis Workers Ratify Contract With Teamsters Local 777: Revolution Cannabis Workers Ratify Contract With Teamsters Local 777

Breaking CBD News: Uncle Bud's to Launch New Premium Health and Wellness Products Leveraging Pressure BioSciences (OTCQB: $PBIO) UltraShear Processing for Revolutionary Product Effectiveness; @ir_pressurebio @UncleBuds_Hemp

 

Breaking CBD News: Uncle Bud's to Launch New Premium Health and Wellness Products Leveraging Pressure BioSciences (OTCQB: $PBIO) UltraShear Processing for Revolutionary Product Effectiveness; @ir_pressurebio @UncleBuds_Hemp

 

Multi-Patented Nanoemulsification Platform Enables Wide-Range of Best-in-Class Health and Wellness Products - Revenue Impact of $5 Million in 2024 Anticipated with Further Acceleration in 2025 & Beyond

 

Pressure BioSciences February 5th Investor Call to Discuss Impact of Recent Uncle Bud's Acquisition

 

SOUTH EASTON, Mass. - February 5, 2024 (Investorideas.com Newswire) Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBIO" or the "Company"), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including health and wellness, nutraceuticals, food and beverage, cosmetics, biotherapeutics, and more, is hosting a teleconference today (Monday, February 5th, 4:30PM EST) to discuss the recent acquisition of natural health and wellness innovator Uncle Bud's ("UB"), as well as other on-going opportunities.

 

Read this in full at https://www.investorideas.com/news/2024/cannabis/02051PBIO-CBD-Body-Revive-Spray.asp

 

CBD Body Revive Spray

 

CBD Body Revive Spray All Natural, Fast Acting, Plant Based, Preservative Free, Best-in-Class, UltraShear-processed Nano CBD

...the first in a series of groundbreaking premium nanoemulsified products designed to meet the needs of consumers looking for the highest quality and performance in natural and effective wellness solutions. Click here for more info on Uncle Bud's Premium Collection.

In an exciting leap forward for natural wellness enthusiasts, Uncle Bud's Health and Wellness ("Uncle Bud's") is announcing the planned launch of its UltraShear-processed "Premium Collection" of state-of-the-art nanoemulsified products. The collection, highlighted by its flagship product - the CBD Body Revive Spray with 1200mg of Nano CBD - will be processed with PBIO's multi-patented UltraShear Technology™ (UltraShear™ or UST™), and is expected to redefine the standards of effectiveness and quality in CBD and other products. These products represent the pinnacle of innovation, quality, and commitment to natural, clean wellness solutions. The Premium Collection launch is expected on or before March 1, 2024.

 

Developed in collaboration with scientists from Uncle Bud's parent PBIO, the UltraShear-processed Premium Collection stands as a testament to Uncle Bud's dedication to harnessing the power of science to amplify the benefits of natural ingredients. By utilizing cutting-edge UltraShear Technology, Premium Collection products will offer unparalleled speed of absorption and delivery of active ingredient dosing payload more efficiently - for faster, more effective results.

 

Embodying Uncle Bud's commitment to safety and environmental responsibility, all UltraShear Premium Collection products will be crafted from 100% natural, clean ingredients, and GMO-free. This meticulous attention to detail guarantees customers receive the highest quality, most sustainable products available for integrating into their daily wellness routines.

 

For the launch of the new premium products, Uncle Bud's is inaugurating a new website category dedicated exclusively to the innovation and quality of the Premium Collection product line. The launch of the initial product - CBD Body Revive Spray with 1200 mg of Nano CBD for powerful, fast-acting relief in a convenient spray form - offers an essential addition in any wellness regimen and marks the beginning of a series of groundbreaking premium products designed to meet the needs of consumers looking for the highest quality and performance in natural and effective wellness solutions.

 

"We are incredibly excited to introduce the UltraShear-processed Premium Collection of innovative, nanoemulsified products to our customers," said Bruno Schiavi, President of Uncle Bud's. "This is a major milestone for us, combining the best of science and nature to create a product line that not only meets but sets a new benchmark for the highest standards of quality, purity, and effectiveness." Click here for more info on Uncle Bud's Premium Collection.

 

John Hollister, PBIO's Director of Sales and Marketing, added: "What an exciting time for all stakeholders in PBIO. With revenues of $5 million anticipated from Uncle Bud's in 2024, combined with revenues of $5 million anticipated from historical PBIO products/services, we believe total 2024 revenues could be 5X or more of our historical annual revenue."

 

Teleconference Information (click here for more conference call details)

• Date: Monday, February 5, 2024. 4:30 pm ET (US).
• Call-in Number: 888-267-2918 (code: 973092).

 

About Uncle Bud's

Launched in 2018 with a trailblazing hemp-based Pain Relief product, Uncle Bud's has rapidly captured an innovative leadership role in the Hemp Seed Oil, Cannabidiol (CBD), and the broader Health & Wellness industry. The Uncle Bud's brand is revered for its unwavering commitment to domestic manufacturing excellence, setting benchmarks for its organic, preservative-free, non-GMO standards and its ethical cruelty-free practices. Uncle Bud's is dedicated to the highest-quality formulations and to continuous improvement, guided by the latest scientific research and development innovations - including the revolutionary performance breakthroughs delivered by PBIO's patented UltraShear™ processing platform. Uncle Bud's diverse product portfolio addresses an ever-broadening spectrum of consumer needs, encompassing pain relief, sophisticated skincare solutions, personal wellness and athletic recovery products, and specialized pet care items. Learn More: www.unclebudshemp.com * Follow On Social Media: @UncleBuds_Hemp.

 

Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. Our products utilize both constant and alternating pressure. Our patented enabling technology platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterrorism applications. We have recently expanded our market opportunities with the acquisition of the BaroFold™ patented technology platform, allowing us to enter the bio-pharma contract services and GMP manufacturing equipment sector. We have also developed the scalable and high-efficiency pressure-based UltraShear Technology™ (UltraShear™) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. Our commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to our customers.

 

Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

 

For more information about PBIO, Uncle Bud's, and this press release, please click on the following website links:
http://www.pressurebiosciences.com www.unclebudshemp.com

Please visit us on Facebook, LinkedIn, and Twitter.

 

Press Contacts

Richard T. Schumacher, President & CEO (508) 230-1828 (T)
Jeffrey N. Peterson, Chairman (650) 812-8121 (T)
Bruno Schiavi, President, PBIO Consumer Products (508) 230-1828 (T)

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure: this news for Pressure BioSciences, Inc. (PBIO) is paid for content on our site. Disclosure More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

 

About Investorideas.com

https://www.investorideas.com/About/

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

Breaking CBD News: Pressure BioSciences (OTCQB: $PBIO) Upcoming Investor Call to Discuss Recent Acquisition of Uncle Buds

  

Breaking CBD News: Pressure BioSciences (OTCQB: $PBIO) Upcoming Investor Call to Discuss Recent Acquisition of Uncle Buds

Uncle Bud's 2024 Revenue Expected to Increase 3-Fold to Approximately $5 Million, Fueled by UltraShear Processed Nanoemulsion Product Introductions and Exciting New Market Opportunities

 

SOUTH EASTON, Mass. - February 1, 2024 (Investorideas.com Newswire) Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBIO" or the "Company"), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including nutraceuticals, food and beverage, health and wellness, cosmetics, biotherapeutics, and more, today announced that the Company will host a teleconference to discuss the recent strategic acquisition of natural health and wellness innovator Uncle Bud's ("UB") in an all-stock transaction. In particular, the Company will discuss its current, in-process move to new, more efficient manufacturing space; the integration plan of the Uncle Bud's team and product offerings into PBIO; and the significant growth expected from new UltraShear processed nanoemulsion products, which are expected to catapult the Company's total revenue by 5X to about $10M in 2024.

Read this news, featuring PBIO in full at https://www.investorideas.com/news/2024/cannabis/02011PBIO-Investor-Call-Recent-Acquisition-Uncle-Buds.asp

 

UltraShear CBD Body Revive Spray

All Natural, Fast Acting, Plant Based, Preservative Free, Best-in-Class Nano CBD

Teleconference Information

• Format: Company presentation followed by Q&A.
• Date: Monday, February 5, 2024. 4:30pm ET (US).
• Call-in Number: 888-267-2918 (code: 973092).
• Replay: PBIO.Replay.020524

Transaction Significance

• Transaction is expected to be immediately accretive and a major accelerator to PBIO's top line revenue growth.
• Combined companies will be positioned to attract new growth investment, rapidly strengthen the balance sheet, accelerate PBIO's path to profitability in 2024, and catalyze PBIO's drive to uplist to NASDAQ/NYSE in 2024.
• UB leadership are experts in branding, spokesperson management, and online/retail multimedia marketing.
• UB will rapidly incorporate PBIO's best-in-class Nano-CBD into renowned and successful CBD product lines.
• Senior management of UB/PBIO plan a dozen new nanoemulsion products for commercial release in 2024.
• UB already markets and sells many products in health & wellness that expand well beyond Hemp and CBD.
• UB continues building ongoing partnership with multi-Grammy award-winning Toni Braxton - highly successful marketing ambassador leaps to embrace combined PBIO/UB as continuing spokesperson.
• UB enjoys strong following for leading hemp and CBD products, in extensive variety of high profile news outlets and magazines online over many years: https://www.unclebudshemp.com/press/.
• UB currently boasts 70+ products, 865K on-line members, and enviable sales channels with leading large retailers.

Expected Financial Impact

• Acquisition combines existing momentum and ready market execution power of Uncle Bud's, with revolutionary product breakthroughs in absorption and speed of action, enabled by PBIO's UltraShear nanoemulsions platform.
• PBIO forecasts Uncle Bud's $1.6 million 2023 revenue tripling to approximately $5 million in 2024.
• PBIO forecasts a 5-fold catapult forward in total Company revenues to approximately $10 million in 2024.

Transaction Terms
Please refer to the Form 8K filed on January 19, 2024.

About Uncle Bud's

Launched in 2018 with a trailblazing hemp-based Pain Relief product, Uncle Bud's has rapidly captured an innovative leadership role in the Hemp Seed Oil, Cannabidiol (CBD), and the broader Health & Wellness industry. The Uncle Bud's brand is revered for its unwavering commitment to domestic manufacturing excellence, setting benchmarks for its organic, preservative-free, non-GMO standards and its ethical cruelty-free practices. Uncle Bud's is dedicated to the highest-quality formulations and to continuous improvement, guided by the latest scientific research and development innovations - including the revolutionary performance breakthroughs delivered by PBIO's patented UltraShear™ processing platform. Uncle Bud's diverse product portfolio addresses an ever-broadening spectrum of consumer needs, encompassing pain relief, sophisticated skincare solutions, personal wellness and athletic recovery products, and specialized pet care items. Learn More: www.unclebudshemp.com * Follow On Social Media: @UncleBuds_Hemp.

Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. Our products utilize both constant and alternating pressure. Our patented enabling technology platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterrorism applications. We have recently expanded our market opportunities with the acquisition of the BaroFold™ patented technology platform, allowing us to enter the bio-pharma contract services and GMP manufacturing equipment sector. We have also developed the scalable and high-efficiency pressure-based UltraShear Technology™ (UltraShear™) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. Our commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to our customers.

Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBIO, Uncle Bud's, and this press release, please click on the following website links:
http://www.pressurebiosciences.com www.unclebudshemp.com
Please visit us on Facebook, LinkedIn, and Twitter.

Press Contacts

Richard T. Schumacher, President & CEO (508) 230-1828 (T)
Jeffrey N. Peterson, Chairman (650) 812-8121 (T)
Bruno Schiavi, President, PBIO Consumer Products (508) 230-1828 (T)

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure: this news for Pressure BioSciences, Inc. (PBIO) is paid for content on our site. Disclosure More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

 

About Investorideas.com

https://www.investorideas.com/About/

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp